|Brand names||Lanzek, Zylap, Zypine, Zyprexa and others|
Olanzapine is an atypical antipsychotic that is notorious for its abnormally high potential to cause weight gain, type II diabetes mellitus and other problems. It has a moderate potential for anticholinergic effects and sedation. It causes less movement disorders and prolactin elevation than most antipsychotics (except aripiprazole, clozapine, melperone and quetiapine), although at higher doses these side effects may be experienced. It is used to treat schizophrenia, bipolar mania, major depression (when it is given in combination with an antidepressant) and bipolar depression (when combined with fluoxetine under the brand name Symbyax). Recent research has suggested it may be effective in treating chemotherapy-induced nausea and vomiting (CINV), especially treatment-resistant forms of CINV.
- DailyMed: Symbyax (package insert)
- NCBI Bookshelf provides free book resources on this topic.
- PubMed provides review articles from the past five years (limit to free review articles or to systematic reviews)
- The TRIP database provides clinical publications about evidence-based medicine.
- TGA eBusiness Services: Lanzek and Lanzek Zydis (CMI, PI), Zyprexa and Zyprexa Zydis (CMI, PI), Zyprexa IM (CMI, PI) and Zyprexa Relprevv (depot; CMI, PI)
- ↑ Silva, MT; Zimmermann, IR; Galvao, TF; Pereira, MG (April 2013). "Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis.". Journal of Affective Disorders 146 (3): 310–8. PMID 23218251. doi:10.1016/j.jad.2012.11.001.
- ↑ Brafford, MV; Glode, A (January 2014). "Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting.". Journal of the Advanced Practitioner in Oncology 5 (1): 24–9. PMC 4093458. PMID 25032030.